Oncotarget

Research Papers: Gerotarget (Focus on Aging):

MiR-21-5p and miR-126a-3p levels in plasma and circulating angiogenic cells: relationship with type 2 diabetes complications

Fabiola Olivieri _, Liana Spazzafumo, Massimiliano Bonafè, Rina Recchioni, Francesco Prattichizzo, Fiorella Marcheselli, Luigina Micolucci, Emanuela Mensà, Angelica Giuliani, Gabriele Santini, Mirko Gobbi, Raffaella Lazzarini, Massimo Boemi, Roberto Testa, Roberto Antonicelli, Antonio Domenico Procopio and Anna Rita Bonfigli

PDF  |  HTML  |  How to cite

Oncotarget. 2015; 6:35372-35382. https://doi.org/10.18632/oncotarget.6164

Metrics: PDF 3314 views  |   HTML 5996 views  |   ?  


Abstract

Fabiola Olivieri1,2, Liana Spazzafumo3, Massimiliano Bonafè4, Rina Recchioni2, Francesco Prattichizzo1, Fiorella Marcheselli2, Luigina Micolucci1, Emanuela Mensà2, Angelica Giuliani1, Gabriele Santini1, Mirko Gobbi1, Raffaella Lazzarini2, Massimo Boemi5, Roberto Testa6, Roberto Antonicelli7, Antonio Domenico Procopio1,2 and Anna Rita Bonfigli8

1 Department of Clinical and Molecular Sciences, DISCLIMO, Università Politecnica delle Marche, Ancona, Italy

2 Center of Clinical Pathology and Innovative Therapy, INRCA-IRCCS National Institute , Ancona, Italy

3 Center of Biostatistics, INRCA-IRCCS National Institute, Ancona, Italy

4 Department of Experimental, Diagnostic and Specialty Medicine, DIMES, University of Bologna, Bologna, Italy

5 Metabolic Diseases and Diabetology Unit, INRCA-IRCCS National Institute, Ancona, Italy

6 Experimental Models in Clinical Pathology, INRCA-IRCCS National Institute, Ancona, Italy

7 UTIC-Cardiology Unit, INRCA-IRCCS National Institute, Ancona, Italy

8 Scientific Direction, INRCA-IRCCS, National Institute, Ancona, Italy

Correspondence to:

Fabiola Olivieri, email:

Keywords: miR-21, miR-126, type 2 diabetes, diabetes complication, circulating miRNAs, Gerotarget

Received: September 10, 2015 Accepted: October 02, 2015 Published: October 19, 2015

Abstract

Innovative biomarkers are required to manage type 2 diabetic patients (T2DM). We focused our study on miR-126-3p and miR-21-5p levels, as biomarkers of endothelial function and inflammation. MiRNAs levels were measured in plasma from 107 healthy subjects (CTR) and 193 diabetic patients (T2DM), 76 without (T2DM NC) and 117 with (T2DM C) complications.

When diabetic complication were analysed as a whole, miR-126-3p and miR-21-5p levels declined significantly from CTR to T2DM NC and T2DM C patients. When miRNAs levels were related to specific complications, significantly higher miR-21-5p levels (0.46 ± 0.44 vs. 0.26±0.33, p < 0.001) and significant lower miR-126-3p levels (0.21±0.21 vs. 0.28±0.22, p = 0.032) were found in T2DM with previous major cardiovascular events (MACE) vs. all the others T2DM patients.

To confirm these results we focused on circulating angiogenic cells (CACs) from a subgroup of 10 CTR, 15 T2DM NC and 15 T2DM patients with MACE. CACs from T2DM patients expressed higher miR-21-5p and lower miR-126-3p levels than CACs from CTR. Furthermore, CACs from T2DM + MACE showed the highest levels of miR-21-5p.

Circulating miR-21-5p and miR-126-3p emerge as dynamic biomarkers of systemic inflammatory/angiogenic status. Their expression levels in CACs from T2DM with MACE suggest a shift from a proangiogenic to a proinflammatory profile.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 6164